Elicera Therapeutics publishes annual report for 2021

February 4, 2022


Gothenburg, January 14, 2022 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company that develops immuno-oncological treatments focused on CAR T-cells and oncolytic viruses, publishes the annual report for 2021.


Elicera Therapeutics annual report is now available at the webpage   https://www.elicera.com.

In the annual report CEO Jamal El-Mosleh comments; ”I look forward to continuing Elicera’s vital efforts in the fight against cancer through developing the next generation of cell and gene therapies, and through ex­panding awareness of our universally compatible CAR T-cell technology platform.”


The Annual General Meeting will be held on March 7t at 3:00 p.m. at the offices of Advokatfirman Delphi (Mäster Samuelsgatan 17 in Stockholm).



For more information, contact:

Jamal El-Mosleh, CEO, Elicera Therapeutics AB (publ)

Tel: +46 (0) 703 31 90 51


About Elicera Therapeutics AB

Elicera Therapeutics AB is a clinical stage cell and gene therapy company developing the next generation of immuno-oncological treatments. The company has four drug candidates in development, two CAR T-cells and two oncolytic viruses, based on research carried out by Professor Magnus Essand’s research group at Uppsala University. In addition, Elicera has a fully developed technology platform, iTANK, which can be used to optimize the effect of all CAR T-cell therapies under development and activate killer T-cells against cancer. The Elicera share (ELIC) is listed on the Nasdaq First North Growth Market. G&W Fondkommission has been appointed the Company's Certified Adviser. E-mail: ca@gwkapital.se, tel: +468-503 000 50.


For more information, please visit www.elicera.se

Download attachment (pdf)
< Back to press releases